Bionano Genomics, Inc. 8-K

What Happened
Bionano Genomics, Inc. announced on January 12, 2026 (via an 8‑K and attached press release) that it reported preliminary financial results for the fourth quarter and fiscal year ended December 31, 2025. The company attached the full press release as Exhibit 99.1 to the Form 8‑K.

Key Details

• Filing date: January 12, 2026 (Current Report on Form 8‑K).
• Item reported: 2.02 — Results of Operations and Financial Condition (preliminary Q4 and FY2025 results).
• Exhibit included: 99.1 — press release reporting preliminary financial results for the quarter and fiscal year ended December 31, 2025.
• 104 — Inline XBRL for the cover page of the Form 8‑K.

Why It Matters
This is the company’s first public disclosure of its preliminary earnings and other year-end financial measures for 2025 and may contain revenue, profitability, or other operating metrics that investors use to assess performance. Retail investors should read the attached press release for the specific figures and any management commentary, as those details can influence expectations for future earnings, valuation, and trading activity.